3. Anxiolytic Effects of Cannabinoids in
the Periaqueductal Gray The PAG is a mesencephalic
structure that surrounds the cerebral aqueduct and can be divided along its rostrocaudal
axis into dorsomedial, dorsolateral (dlPAG), lateral, and ventrolateral columns
[ 29]. It is an important site in ascending pain transmission and a major component of a descending pain inhibitory system. Moreover, this structure
receives glutamatergic projection from forebrain regions and sends descendent
pathways to motor outputs and to autonomic centres that control blood pressure
and heart rate [ 26]. The dorsal columns (dPAG) are possibly responsible for the
elaboration of active defensive behaviors (see [ 26], for review). Lesions of
the dPAG inhibit fear and anxiety produced by stimulation of the amygdala whereas
stimulation of this region induces threat display associated with vocalization
and strong flight responses [ 26]. In the caudal ventrolateral PAG, however,
immobility has been described as the main outcome of local stimulation [ 30]. CB1 receptors are distributed
along the various columns of this structure [ 13]. Moreover, administration of
CB1 agonists increases Fos expression [ 31] and brain metabolic activity in the
PAG of rats [ 32], suggesting that this structure could be involved in the
effects of systemically administered cannabinoids. In agreement with this
proposal, injection of CB1 receptor agonists into the dlPAG of rats has been
shown to induce antinociceptive responses [ 33] and electric stimulation of the
dorsal and lateral columns induces antinociception via activation of CB1
receptors accompanied by local AEA release [ 34]. Furthermore, subcutaneous
formalin injection, a painful stimulus, substantially increased the release of AEA
in the PAG [ 34, 35]. Concerning the possible
involvement of PAG-endocannabinoid system on modulation of anxiety-like behaviors,
an initial study showed that local administration of HU210, a potent CB1
agonist, attenuated the flight responses induced by dPAG injections of the
excitatory amino acid D,L-homocysteic acid (see [ 36, Table 2]). In a subsequent
study, where the injections were restricted to the dorsomedial PAG, HU210
decreased hyperlocomotion induced by aversive ultrasound stimulation, but
failed to change freezing responses. Moreover, HU210 effects were not entirely blocked
by previous local injection of a CB1 receptor antagonist [ 70]. Considering these initial
results, we decided to further investigate a possible influence of the
PAG-endocannabinoid system on anxiety-like behaviors in rats submitted to
different animal models of anxiety ( Table 2). First, we showed that AEA
injected into the dlPAG increased the exploration of the open arms of the
elevated plus maze (EPM) [ 71], a model based on a natural conflict between
exploratory behavior and innate fear of open spaces. The effects of AEA were
similar to those observed with classical anxiolytic benzodiazepines [ 72] and
were blocked by previous treatment with AM251, a CB1 receptor antagonist. These
effects were also potentiated by previous treatment with AM404, an inhibitor of
AEA uptake/metabolism. AM404 by itself, however, was without effect in this
model. AEA produced an inverted U-shaped dose-response curve, with higher doses
being ineffective [ 71]. ![Table 2 Table 2](corehtml/pmc/pmcgifs/table-icon.gif) | Table 2Effects of Cannabinoid-related drugs injected
into the PAG of rats submitted to animal models of anxiety-related behaviors. (AEA:
anandamide; ACEA: arachidonyl-2-chloro-ethylamide; CBD: cannabidiol; EPM:
elevated plus-maze; VCT: Vogel conflict test; CFC: (more ...) |
To confirm a possible
anticonflict effect of AEA in the dlPAG, we used the Vogel conflict test (VCT)
[ 73], an animal model of anxiety not based on innate fear but instead on
suppression of punished responses learned during the test. In this model, water-deprived
rodents are exposed to a conflict between licking the spout of a bottle
containing water and receiving a mild shock on the tong [ 74]. Anxiolytics that
potentiate the action of γ-aminobutyric acid
such as the benzodiazepines typically increase the number of punished licks [ 75].
AEA also induced anxiolytic-like effects in the VCT at the same dose range
observed in the EPM ( Table 2). Different from the results obtained in the latter
model, AM404 was also able to increase the number of punished licks ( Table 2).
Although the causes of these contradictory results are not clear, they could
involve the distinct animal models of anxiety employed. Brain endocannabinoids
have been proposed to act as a “stress buffer system” [ 76], recruited by highly
demanding situations. It was possible that the VCT, by involving pain and water
deprivation, engages the endocannabinoid system in the dlPAG to a greater extent
than the EPM. Actually, as discussed above, painful stimuli such as those used
in the VCT have already been showed to increase AEA in this region [ 77]. We have further investigated
this effect by intra-dlPAG administration of AEA and AM404 in rats submitted to
a contextual fear conditioning paradigm, an animal model that also involves
pain exposure [ 78]. Animals re-exposed to an environment where they had being
previously submitted to an aversive stimulation, such as electrical footshocks,
show behavioral and cardiovascular changes characterized by immobility
(freezing) and mean arterial pressure (MAP) and heart rate (HR) increases [ 79, 80].
Although electrical or chemical stimulation of the dorsal portion of PAG is
usually related with flight reactions, it can also produce freezing responses
and increased cardiovascular activity [ 26]. Re-exposure to an aversively
conditioned context increases neuronal activity in the PAG [ 81, 82], and PAG
lesions block freezing to aversively conditioned stimulus [ 83, 84]. dlPAG
microinjection of AEA or AM404 blocked the expression of the conditioned
aversive responses [ 78]. This effect was inhibited by local pretreatment with
AM251, reinforcing the involvement of CB1 receptors. Altogether, these results
suggest that the endocannabinoid system in the dlPAG can modulate responses to
aversive stimuli. The mechanisms of these effects are still unclear. Using
brain slices of the rat PAG, Vaughan et al. [ 85] showed that cannabinoids act
via CB1 receptors to inhibit GABAergic and glutamatergic synaptic transmission.
The efficacy of endogenous cannabinoids was limited by uptake and breakdown
since AEA was only able to inhibit evoked inhibitory postsynaptic currents in
the presence of the AT inhibitor, AM404. Several studies indicate that GABA-
and glutamate-mediated neurotransmissions in the dPAG play opposite roles.
While the former tonically inhibits defensive responses, the latter facilitates
them [ 26]. Thus, CB1-mediated inhibitory effects on these two neurotransmitter
systems could be one of the explanations for the observed bell-shaped
dose-response curve induced by AEA in this region as well as the contradictory
results regarding the effects of cannabinoids on anxiety (see Table 1 and text bellow for a discussion on the possible involvement of TRPV1 receptors). These mechanisms may explain
the effects in the PAG, yet they do not necessarily apply to other brain
regions. In some areas, the levels of CB1 receptor expression can be higher in GABAergic
(particularly in cholecystokinin-containing basket cells) as compared to
glutamatergic neurons, with cannabinoid effects favoring impairment of inhibitory
mechanisms mediated by the former neuronal population [ 16]. However, it remains
to be further investigated how these neural subpopulations contribute to specific
behavioral effects of cannabinoids. In addition, GABAergic and glutamatergic
neurons may have different sensitivity to CB1 agonists or antagonists depending
on the species under investigation. For instance, Haller et al. [ 52] observed opposite
effects in mice and rats tested with the same doses of a cannabinoid in models
of anxiety-like behavior (see Table 1). Inhibitory and excitatory currents were
differentially affected in the hippocampi of these species, providing a
possible basis for the discrepancies in the behavioral responses. Since we have
employed rats as subjects in all our experiments, studies in other species could
further consolidate our hypothesis that glutamatergic and GABAergic inhibitions
would mediate anxiolytic- and anxiogenic-like effects of cannabinoids, respectively.
For a more extensive discussion on the relevance of diverse neural
subpopulations for the effects of cannabinoids, see [ 89]. |
References 1. Booth M. Cannabis: A History. London, UK: Banton Books; 2003. 2. Courtwright DT. Forces of Habit: Drugs and the Making of the Modern World. Cambridge, Mass, USA: Harvard University Press; 2001. 3. Zuardi AW. History of cannabis as a medicine: a review. Revista Brasileira de Psiquiatria. 2006;28(2):153–157. [PubMed]4. Mechoulam R. Marijuana chemistry. Science. 1970;168(936):1159–1166. [PubMed]5. Paton WDM. Pharmacology of marijuana. Annual Review of Pharmacology. 1975;15:191–220. 6. Devane WA, Dysarz FA, III, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology. 1988;34(5):605–613. [PubMed]7. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561–564. [PubMed]8. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–1949. [PubMed]9. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology. 1995;50(1):83–90. [PubMed]10. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–65. [PubMed]11. Rinaldi-Carmona M, Barth F, Héaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters. 1994;350(2-3):240–244. [PubMed]12. Gatley SJ, Gifford AN, Volkow ND, Lan R, Makriyannis A.
123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB 1 receptors. European Journal of Pharmacology. 1996;307(3):331–338. [PubMed]13. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. The Journal of Neuroscience. 1991;11(2):563–583. [PubMed]14. Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83(2):393–411. [PubMed]15. Egertov M, Giang DK, Cravatt BF, Elphick MR. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proceedings of the Royal Society B. 1998;265(1410):2081–2085. [PubMed]16. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001;410(6828):588–592. [PubMed]17. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews. 2002;54(2):161–202. [PubMed]18. Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. Journal of Pharmacology and Experimental Therapeutics. 2001;298(1):7–14. [PubMed]19. McKinney MK, Cravatt BE. Structure and function of fatty acid amide hydrolase. Annual Review of Biochemistry. 2005;74:411–432. 20. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews. 2006;58(3):389–462. [PubMed]21. Brown AJ. Novel cannabinoid receptors. British Journal of Pharmacology. 2007;152(5):567–575. [PubMed]22. Price MR, Baillie GL, Thomas A, et al. Allosteric modulation of the cannabinoid CB 1 receptor. Molecular Pharmacology. 2005;68(5):1484–1495. [PubMed]23. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB 2 receptors. Science. 2005;310(5746):329–332. [PubMed]24. Gong J-P, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Research. 2006;1071(1):10–23. [PubMed]25. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacology Biochemistry and Behavior. 2005;81(2):331–342. 26. Graeff FG. Neuroanatomy and neurotransmitter regulation of defensive behaviours and related emotions in mammals. Brazilian Journal of Medical and Biological Research. 1994;27(4):811–829. [PubMed]27. McNaughton N, Gray JA. Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. Journal of Affective Disorders. 2000;61(3):161–176. [PubMed]28. McNaughton N, Corr PJ. A two-dimensional neuropsychology of defense: fear/anxiety and defensive distance. Neuroscience & Biobehavioral Reviews. 2004;28(3):285–305. [PubMed]29. Bandler R, Keay KA, Floyd N, Price J. Central circuits mediating patterned autonomic activity during active vs. passive emotional coping. Brain Research Bulletin. 2000;53(1):95–104. [PubMed]30. Bandler R, Depaulis A. Elicitation of intraspecific defence reactions in the rat from midbrain periaqueductal grey by microinjection of kainic acid, without neurotoxic effects. Neuroscience Letters. 1988;88(3):291–296. [PubMed]31. Patel NA, Moldow RL, Patel JA, Wu G-D, Chang SL. Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain. Brain Research. 1998;797(2):225–233. [PubMed]32. Chin C-L, Tovcimak AE, Hradil VP, et al. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. British Journal of Pharmacology. 2008;153(2):367–379. [PubMed]33. Martin WJ, Patrick SL, Coffin PO, Tsou K, Walker JM. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sciences. 1995;56(23-24):2103–2109. [PubMed]34. Walker JM, Huang SM, Strangman NM, Tsou K, Sañudo-Peña MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(21):12198–12203. [PubMed]35. Hohmann AG, Suplita RL., II Endocannabinoid mechanisms of pain modulation. The AAPS Journal. 2006;8(4):E693–E708. [PubMed]36. Finn DP, Jhaveri MD, Beckett SRG, et al. Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology. 2003;45(5):594–604. [PubMed]37. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. Journal of Pharmacology and Experimental Therapeutics. 1990;253(3):1002–1009. [PubMed]38. Valjent E, Mitchell JM, Besson M-J, Caboche J, Maldonado R. Behavioural and biochemical evidence for interactions between Δ 9-tetrahydrocannabinol and nicotine. British Journal of Pharmacology. 2002;135(2):564–578. [PubMed]39. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Δ 9-tetrahydrocannabinol. Psychopharmacology. 2002;163(1):111–117. [PubMed]40. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signalling. Journal of Pharmacology and Experimental Therapeutics. 2006;318(1):304–311. [PubMed]41. Braida D, Limonta V, Malabarba L, Zani A, Sala M. 5-HT 1A receptors are involved in the anxiolytic effect of Δ 9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. European Journal of Pharmacology. 2007;555(2-3):156–163. [PubMed]42. Schramm-Sapyta NL, Cha YM, Chaudhry S, Wilson WA, Swartzwelder HS, Kuhn CM. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology. 2007;191(4):867–877. [PubMed]43. Rubino T, Sala M, Viganò D, et al. Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Δ 9-tetrahydrocannabinol in rats. Neuropsychopharmacology. 2007;32(9):2036–2045. [PubMed]44. Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology. 1990;100(4):558–559. [PubMed]45. Guimarães FS, de Aguiar JC, Mechoulam R, Breuer A. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. General Pharmacology. 1994;25(1):161–164. [PubMed]46. Moreira FA, Aguiar DC, Guimarães FS. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2006;30(8):1466–1471. [PubMed]47. Resstel LB, Joca SRL, Moreira FA, Corrêaa FMA, Guimarães FS. Effects of cannabidiol and diazepam on behavioural and cardiovascular responses induced by contextual conditioned fear in rats. Behavioural Brain Research. 2006;172(2):294–298. [PubMed]48. Giuliani D, Ferrari F, Ottani A. The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacological Research. 2000;41(1):45–51. [PubMed]49. Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. The Journal of Clinical Investigation. 2005;115(11):3104–3116. [PubMed]50. Hill MN, Gorzalka BB. Enhancement of anxiety-like responsiveness to the cannabinoid CB 1 receptor agonist HU-210 following chronic stress. European Journal of Pharmacology. 2004;499(3):291–295. [PubMed]51. Haller J, Varga B, Ledent C, Freund TF. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behavioural Pharmacology. 2004;15(4):299–304. [PubMed]52. Haller J, Mátyás F, Soproni K, et al. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. European Journal of Neuroscience. 2007;25(8):2445–2456. [PubMed]53. Arévalo C, de Miguel R, Hernández-Tristán R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacology Biochemistry and Behavior. 2001;70(1):123–131. 54. Marín S, Marco E, Biscaia M, et al. Involvement of the κ-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacology Biochemistry and Behavior. 2003;74(3):649–656. 55. Marco EM, Pérez-Alvarez L, Borcel E, et al. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behavioural Pharmacology. 2004;15(1):21–27. [PubMed]56. Genn RF, Tucci S, Marco E, Viveros M-P, File SE. Anxiolytic and anxiogenic effects of the cannabinoid agonist CP 55,940 in animal tests of anxiety. Journal of Psychopharmacology. 2003;17:p. A27. 57. Genn RF, Tucci S, Marco EM, Viveros MP, File SE. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacology Biochemistry and Behavior. 2004;77(3):567–573. 58. Chakrabarti A, Ekuta JE, Onaivi ES. Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice. Brain Research Bulletin. 1998;45(1):67–74. [PubMed]59. Scherma M, Medalie J, Fratta W, et al. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology. 2008;54(1):129–140. [PubMed]60. Bortolato M, Campolongo P, Mangieri RA, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology. 2006;31(12):2652–2659. [PubMed]61. Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nature Medicine. 2003;9(1):76–81. [PubMed]62. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology. 2007;192(1):61–70. [PubMed]63. Moreira FA, Kaiser N, Monory K, Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology. 2008;54(1):141–150. [PubMed]64. Rutkowska M, Jamontt J, Gliniak H. Effects of cannabinoids on the anxiety-like response in mice. Pharmacological Reports. 2006;58(2):200–206. [PubMed]65. Navarro M, Hernández E, Muñoz RM, et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. NeuroReport. 1997;8(2):491–496. [PubMed]66. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. European Journal of Neuroscience. 2002;16(7):1395–1398. [PubMed]67. Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biological Psychiatry. 2005;57(3):261–267. [PubMed]68. Rodgers RJ, Evans PM, Murphy A. Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice. Behavioural Pharmacology. 2005;16(5-6):405–413. [PubMed]69. Kasckow JW, Mulchahey JJ, Geracioti TD., Jr. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviours. Progress in Neuropsychopharmacology and Biological Psychiatry. 2004;28(2):291–295. 70. Finn DP, Jhaveri MD, Beckett SRG, Kendall DA, Marsden CA, Chapman V. Cannabinoids modulate ultrasound-induced aversive responses in rats. Psychopharmacology. 2004;172(1):41–51. [PubMed]71. Moreira FA, Aguiar DC, Guimarães FS. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology. 2007;52(3):958–965. [PubMed]72. Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacology Biochemistry and Behavior. 1986;24(3):525–529. 73. Lisboa SF, Resstel LB, Aguiar DC, Guimarães FS. Activation of cannabinoid CB 1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. European Journal of Pharmacology. 2008;593(1–3):73–78. [PubMed]74. Vogel JR, Beer B, Clody DE. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia. 1971;21(1):1–7. [PubMed]75. Millan MJ. The neurobiology and control of anxious states. Progress in Neurobiology. 2003;70(2):83–244. [PubMed]76. Viveros M-P, Marco E-M, Llorente R, López-Gallardo M. Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plasticity. 2007;2007:12 pages. Article ID 52908. 77. Hohmann AG, Suplita RL, Bolton NM, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature. 2005;435(7045):1108–1112. [PubMed]78. Resstel LB, Lisboa SF, Aguiar DC, Corrêa FMA, Guimarães FS. Activation of CB1 cannabinoid receptors in the dorsolateral periaqueductal gray reduces the expression of contextual fear conditioning in rats. Psychopharmacology. 2008;198(3):405–411. [PubMed]79. Fanselow MS. Conditional and unconditional components of post-shock freezing. The Pavlovian Journal of Biological Science. 1980;15(4):177–182. [PubMed]80. Resstel LB, Joca SR, Guimarães FG, Corrêa FMA. Involvement of medial prefrontal cortex neurons in behavioural and cardiovascular responses to contextual fear conditioning. Neuroscience. 2006;143(2):377–385. [PubMed]81. Carrive P, Lee J, Su A. Lidocaine blockade of amygdala output in fear-conditioned rats reduces Fos expression in the ventrolateral periaqueductal gray. Neuroscience. 1999;95(4):1071–1080. [PubMed]82. Carrive P, Leung P, Harris J, Paxinos G. Conditioned fear to context is associated with increased Fos expression in the caudal ventrolateral region of the midbrain periaqueductal gray. Neuroscience. 1997;78(1):165–177. [PubMed]83. Amorapanth P, Nader K, LeDoux JE. Lesions of periaqueductal gray dissociate-conditioned freezing from conditioned suppression behaviour in rats. Learning & Memory. 1999;6(5):491–499. [PubMed]84. LeDoux JE, Iwata J, Cicchetti P, Reis DJ. Different projections of the central amygdaloid nucleus mediate autonomic and behavioural correlates of conditioned fear. The Journal of Neuroscience. 1988;8(7):2517–2529. [PubMed]85. Vaughan CW, Connor M, Bagley EE, Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Molecular Pharmacology. 2000;57(2):288–295. [PubMed]86. Campos AC, Guimarães FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology. 2008;199(2):223–230. [PubMed]87. Terzian AL, Aguiar DC, Guimarães FS, Moreira FA. Modulation of anxiety-like behaviour by Transient Receptor Potential
Vanilloid Type 1 Channel (TRPV1) located in the dorsolateral
periaqueductal gray. European Neuropsychopharmacology. In press. 88. Canteras NS. The medial hypothalamic defensive system: hodological organization and functional implications. Pharmacology Biochemistry and Behavior. 2002;71(3):481–491. 89. Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addiction Biology. 2008;13(2):196–212. [PubMed]90. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by Δ 9-THC in normal subjects. Psychopharmacology. 1982;76(3):245–250. [PubMed]91. Zuardi AW, Crippa JAS, Hallak JEC, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian Journal of Medical and Biological Research. 2006;39(4):421–429. [PubMed]92. Zuardi AW, Cosme RA, Graeff FG, Guimarães FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. Journal of Psychopharmacology. 1993;7(1):82–88. 93. de Souza Crippa JA, Zuardi AW, Garrido GEJ, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004;29(2):417–426. [PubMed]94. Bisogno T, Hanuš L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology. 2001;134(4):845–852. [PubMed]95. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochemical Research. 2005;30(8):1037–1043. [PubMed]96. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience. 2006;139(4):1405–1415. [PubMed]97. Nogueira RL, Graeff FG. Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion. Pharmacology Biochemistry and Behavior. 1995;52(1):1–6. 98. Raymond JR, Mukhin YV, Gettys TW, Garnovskaya MN. The recombinant 5-HT 1A receptor: G protein coupling and signalling pathways. British Journal of Pharmacology. 1999;127(8):1751–1764. [PubMed]99. Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. European Journal of Pharmacology. 2003;463(1–3):235–272. [PubMed]100. Zanoveli JM, Nogueira RL, Zangrossi H., Jr. Serotonin in the dorsal periaqueductal gray modulates inhibitory avoidance and one-way escape behaviours in the elevated T-maze. European Journal of Pharmacology. 2003;473(2-3):153–161. [PubMed]101. de Paula Soares V, Zangrossi H., Jr. Involvement of 5-HT 1A and 5-HT 2 receptors of the dorsal periaqueductal gray in the regulation of the defensive behaviours generated by the elevated T-maze. Brain Research Bulletin. 2004;64(2):181–188. [PubMed]102. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389(6653):816–824. [PubMed]103. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacology Reviews. 1999;51(2):159–212. 104. van der Stelt M, Di Marzo V. Endovanilloids: putative endogenous ligands of transient receptor potential vanilloid 1 channels. European Journal of Biochemistry. 2004;271(10):1827–1834. [PubMed]105. Marinelli S, Di Marzo V, Florenzano F, et al.
N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology. 2007;32(2):298–308. [PubMed]106. Mezey É, Tóth ZE, Cortright DN, et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(7):3655–3660. [PubMed]107. McGaraughty S, Chu KL, Bitner RS, et al. Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM. Journal of Neurophysiology. 2003;90(4):2702–2710. [PubMed]108. Palazzo E, de Novellis V, Marabese I, et al. Interaction between vanilloid and glutamate receptors in the central modulation of nociception. European Journal of Pharmacology. 2002;439(1–3):69–75. [PubMed]109. Xing J, Li J. TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. Journal of Neurophysiology. 2007;97(1):503–511. [PubMed]110. Molchanov ML, Guimarães FS. Anxiolytic-like effects of AP7 injected into the dorsolateral or ventrolateral columns of the periaqueductal gray of rats. Psychopharmacology. 2002;160(1):30–38. [PubMed]111. Marsch R, Foeller E, Rammes G, et al. Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. The Journal of Neuroscience. 2007;27(4):832–839. [PubMed]112. Micale V, Cristino L, Tamburella A, et al. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology. In press. 113. Rubino T, Realini N, Castiglioni C, et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cerebral Cortex. 2008;18(6):292–301. 114. Rubino T, Guidali C, Vigano D, et al. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology. 2008;54(1):151–160. [PubMed]115. Onaivi ES, Chakrabarti A, Gwebu ET, Chaudhuri G. Neurobehavioral effects of Δ 9-THC and cannabinoid (CB1) receptor gene expression in mice. Behavioural Brain Research. 1996;72(1-2):115–125. [PubMed] |